Processa Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
PCSA$1.95+1.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating Expenses | ||
| Research and development expenses | $5,799,518 | $11,494,230 |
| General and administrative expenses | 5,657,543 | 8,763,058 |
| Impairment of intangible asset | - | 7,268,143 |
| Operating Loss | (11,457,061) | (27,525,431) |
| Other Income (Expense) | ||
| Interest income, net | 335,541 | 101,202 |
| Net Operating Loss Before Income Tax Benefit | (11,121,520) | (27,424,229) |
| Income Tax Benefit | - | - |
| Net Loss | $(11,121,520) | $(27,424,229) |
| Net Loss Per Common Share - Basic and Diluted | $(8.48) | $(34.05) |
| Weighted Average Common Shares Used to Compute | ||
| Net Loss Per Common Shares - Basic and Diluted | 1,311,572 | 805,477 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.